Actively Recruiting
Venetoclax Combined With Azactidine in the Treatment of ALAL
Led by Sheng-Li Xue, MD · Updated on 2025-12-16
23
Participants Needed
1
Research Sites
139 weeks
Total Duration
On this page
Sponsors
S
Sheng-Li Xue, MD
Lead Sponsor
J
Jining Medical University
Collaborating Sponsor
AI-Summary
What this Trial Is About
The prognosis of acute leukaemias of ambiguous lineage is poor. The effect of chemotherapy regimen and hematopoietic stem cell transplantation are still unclear. Therefore, we will explore new therapy to improve the remission rate of acute leukaemias of ambiguous lineage. Venetoclax can significantly improve the remission rate and prolong PFS and OS. At present, venetoclax combined with azacitidine or decitabine has become the preferred treatment regimen for elderly AML patients. It also shows a high response rate in relapsed/refractory AML or MDS patients. There are few clinical studies on the treatment of ALAL. The purpose of this study is to explore the efficacy and safety of venetoclax combined with azacitidine in the treatment of newly diagnosed ALAL patients.
CONDITIONS
Official Title
Venetoclax Combined With Azactidine in the Treatment of ALAL
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients aged 6 15 years.
- Diagnosed with ALAL according to the 5th edition of WHO standards.
- Newly diagnosed ALAL patients.
- ECOG performance status score less than 3.
- Expected survival time of at least 3 months.
- No serious heart, lung, liver, or kidney disease.
- Ability to understand and voluntarily provide informed consent.
You will not qualify if you...
- Allergy to the study drug or similar drugs.
- Pregnant or breastfeeding women, or women of childbearing age not using effective contraception.
- Active infection.
- Active bleeding.
- New thrombosis, embolism, cerebral hemorrhage, or related history within one year before enrollment.
- Mental disorders or conditions preventing informed consent or study compliance.
- Liver function abnormalities above specified limits or renal anomalies.
- History of significant heart rhythm problems, heart attack within one year, congestive heart failure, or symptomatic coronary heart disease.
- Surgery on main organs within the past six weeks.
- Drug or long-term alcohol abuse affecting evaluation.
- History of organ transplantation (except bone marrow).
- Considered unsuitable by the investigator.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The First Affliated Hospital of Soochow University
Suzhou, China
Actively Recruiting
Research Team
S
Sheng-Li Xue, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here